Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current progress in beta-amyloid immunotherapy.

Dale Schenk1, Michael Hagen, Peter Seubert

  • 1Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, California 94080, USA. dale.schenk@elan.com

Current Opinion in Immunology
|September 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Acta neuropathologica communications·2026
Same author

Effects of α-Synuclein Immunization in a Mouse Model of Parkinson's Disease.

Neuron·2025
Same author

Extreme Heat and Air Quality: Community Leader Perspectives on Information Barriers and Opportunities in Two Environmental Justice Communities.

New solutions : a journal of environmental and occupational health policy : NS·2024
Same author

Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions.

Scientific reports·2019
Same author

Comparison of AR, ITS, CBT, and Didactic Training and Evaluation of Retinopathy-Based Diagnosis.

Military medicine·2019
Same author

The Prevalence of Asymptomatic Cervical and Lumbar Facet Arthropathy: A Computed Tomography Study.

Asian spine journal·2019

Beta-amyloid (Abeta) immunotherapy shows promise for Alzheimer's disease (AD), challenging the idea of brain immune privilege. This approach is advancing clinical trials and exploring the immune system's role in neurodegeneration.

Area of Science:

  • Neuroscience
  • Immunology
  • Neurology

Background:

  • The brain was traditionally considered immune privileged, separate from the peripheral immune system.
  • Initial findings on beta-amyloid (Abeta) immunotherapy in Alzheimer's disease (AD) models were met with surprise.

Purpose of the Study:

  • To investigate the effectiveness of Abeta immunotherapy in Alzheimer's disease models.
  • To explore the implications of Abeta immunotherapy for the amyloid hypothesis of AD.
  • To examine the broader role of the immune system in neurodegenerative diseases.

Main Methods:

  • Utilizing Abeta-based immunogens in AD mouse models.
  • Employing anti-Abeta antibodies for therapeutic intervention.
  • Conducting clinical trials for Abeta immunotherapy in human AD patients.

Related Experiment Videos

Main Results:

  • Multiple research groups have confirmed the efficacy of Abeta immunotherapy in AD models.
  • Ongoing clinical trials are generating significant data on Abeta immunotherapy's effects.
  • Evidence supports the effectiveness of Abeta immunotherapy in reducing amyloid pathology.

Conclusions:

  • Abeta immunotherapy is a viable therapeutic strategy for Alzheimer's disease.
  • The brain's immune privilege is not absolute, and peripheral immunity plays a role.
  • Further research is needed to understand the immune system's involvement in neurodegeneration.